Navigation Links
Pharmacyclics Announces Promising Results From Phase 2 Clinical,Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung,Cancer

nd the product development of our pipeline; the possibility that the FDA refuses to approve our NDA; because our Phase 3 clinical trial known as the SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial failed to meet its primary endpoint, the FDA may require additional data, analysis or studies before the NDA is approved by the FDA; the outcome of any discussions with the FDA; the initiation, timing, design, enrollment and cost of clinical trials; unexpected delays in clinical trials and preparation of materials for submission to the FDA as part of our NDA filing; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2006 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, Inc., +1-415-225-5050, forPharmacyclics, Inc.

Web site: http://www.pharmacyclics.com/http://www.yourcanceryourchoice.com/

Ticker Symbol: (NASDAQ-NMS:PCYC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/2/2015)... , July 2, 2015   BioLife Solutions , Inc. ... of proprietary clinical grade cell and tissue hypothermic storage ... cloud hosted biologistics cold chain management app for ... that Seattle Business Magazine has included BioLife in ... for in Washington state for 2015. ...
(Date:7/2/2015)... ATLANTA , July 2, 2015 Legal-Bay ... U.S. District Judge Joseph Goodwin in the ... (VA) consolidated 26 transvaginal mesh cases against Ethicon for ... nd . The cases for the 26 women include ... by a device made my Johnson & Johnson,s Ethicon ...
(Date:7/1/2015)... The Coalition of State Rheumatology Organizations ... professional rheumatology societies, today released the findings of ... of biosimilars and the potential impact of these ... are medicines that are highly similar, but not ... from generic medications in that it is impossible ...
Breaking Medicine Technology:BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 3Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2
... eCardio announced today their inclusion on the Inc. ... Inc. 500. Inc. magazine released the list on ... with a three-year sales growth of 642%. ... http://www.newscom.com/cgi-bin/prnh/20100817/INC5000LOGO ) The list represents ...
... Inc. (Nasdaq: BMRN ) announced today that ... Food and Drug Administration (FDA) for BMN-701, a novel ... (IGF2-GAA) in development for the treatment of Pompe disease. ... been submitted, investigational material has been manufactured and a ...
Cached Medicine Technology:Inc. Magazine Unveils 29th Annual List of America's Fastest-Growing Private Companies—the Inc. 500 2Inc. Magazine Unveils 29th Annual List of America's Fastest-Growing Private Companies—the Inc. 500 3BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease 2BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease 3
(Date:7/2/2015)... ... ... The ZAC Foundation, a national leader in water safety education and drowning ... stay water safe with the help of a young polar bear named Zeke. ... follows Zeke’s water safety journey. Zeke, who is afraid of the water and ...
(Date:7/2/2015)... ... July 02, 2015 , ... When ... met for the late June Web-based session, the speakers discussed the importance of ... managing high-risk patients through coordinated care. , During the session, participants learned the ...
(Date:7/2/2015)... La Mirada, CA (PRWEB) , ... July 02, ... ... the addition of Dr. Divakar R. Krishnareddy, M.D., to the orthopedic and spine ... fractures, dislocations, disc herniations, sprains, strains, bursitis, and tendonitis. Along with the spine ...
(Date:7/2/2015)... ... 02, 2015 , ... Facial plastic surgery is about more ... an art and science that goes into successful facial reconstruction and contouring. Dr. ... and lives of more than 2,500 satisfied facelift and neck lift patients alone. ...
(Date:7/2/2015)... , ... July 02, 2015 , ... ... Tunnel treatment and wrist pain treatment. Dr. Lev Kalika, founder of New ... a leading international authority on the conservative treatment of back, hip, knee and ...
Breaking Medicine News(10 mins):Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 4Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4
... N.C., May 9 The cost to replace an,employee ... but the long-term cost,to the organization,s Service-Profit Chain is ... the effects of turnover on the,bottom line and offers ... tremendously improve productivity and the overall customer,experience. According to ...
... 9 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a,clinical ... of cancer therapies, today announced its 2008 ... Highlights, During the three months ended ... steps in preparation for the upcoming multi-center ...
... CCH, part of Wolters Kluwer Law,& Business, has ... Crisis: Causes and Effects of the Mortgage Meltdown, ... Wolters Kluwer Law &,Business is a leading provider ... areas for legal and business professionals., In ...
... cuts to the,Medicare physician fee schedule could severely ... rehabilitation needs of seniors and people,with disabilities -- ... according to the American Physical Therapy Association (APTA) ... 8 before a hearing of the U.S. House ...
... ... Reforms - ,Medicare for All, OAKLAND, Calif., May ... -- and the nation,s largest union of RNs,-- Bill Moyers, ... for guaranteed,single-payer healthcare in an episode scheduled to air this ...
... Women suffering with postpartum depression may in future be ... over the phone, eliminating barriers to treatment such as ... psychiatrist. , Dr. Cindy-Lee Dennis, Canada Research Chair in ... of Nursing, University of Toronto, is the lead investigator ...
Cached Medicine News:Health News:Employee Engagement & Retention: Benchmarking Metrics and Networking Opportunity to Help Solve Today's Workforce Challenges 2Health News:Bradmer announces 2008 first quarter operational and financial results 2Health News:Bradmer announces 2008 first quarter operational and financial results 3Health News:Bradmer announces 2008 first quarter operational and financial results 4Health News:Bradmer announces 2008 first quarter operational and financial results 5Health News:Bradmer announces 2008 first quarter operational and financial results 6Health News:Bradmer announces 2008 first quarter operational and financial results 7Health News:Bradmer announces 2008 first quarter operational and financial results 8Health News:CCH White Paper Details Subprime Crisis, Wider Effects 2Health News:Medicare Fee Cuts Could Devastate Rehabilitation Services, Physical Therapists Warn Congress 2Health News:Medicare Fee Cuts Could Devastate Rehabilitation Services, Physical Therapists Warn Congress 3Health News:Medicare Fee Cuts Could Devastate Rehabilitation Services, Physical Therapists Warn Congress 4Health News:Bill Moyers' Journal to Feature California Nurses Association/National Nurses Organizing Committee in Friday, May 9th Episode 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: